Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Capital Leases (2016 - 2021)

Historic Capital Leases for Adma Biologics (ADMA) over the last 10 years, with Q1 2021 value amounting to $6.4 million.

  • Adma Biologics' Capital Leases rose 25048.33% to $6.4 million in Q1 2021 from the same period last year, while for Mar 2021 it was $6.4 million, marking a year-over-year increase of 25048.33%. This contributed to the annual value of $4.3 million for FY2020, which is N/A changed from last year.
  • Per Adma Biologics' latest filing, its Capital Leases stood at $6.4 million for Q1 2021, which was up 25048.33% from $4.3 million recorded in Q4 2020.
  • In the past 5 years, Adma Biologics' Capital Leases ranged from a high of $6.4 million in Q1 2021 and a low of $15319.0 during Q1 2017
  • In the last 5 years, Adma Biologics' Capital Leases had a median value of $1.4 million in 2019 and averaged $2.0 million.
  • Per our database at Business Quant, Adma Biologics' Capital Leases skyrocketed by 95341.3% in 2019 and then surged by 2533.01% in 2020.
  • Adma Biologics' Capital Leases (Quarter) stood at $15319.0 in 2017, then soared by 677.34% to $119080.0 in 2018, then soared by 1039.06% to $1.4 million in 2019, then skyrocketed by 219.54% to $4.3 million in 2020, then surged by 48.12% to $6.4 million in 2021.
  • Its last three reported values are $6.4 million in Q1 2021, $4.3 million for Q4 2020, and $2.9 million during Q3 2020.